Genspera Inc (OTCMKTS:GNSZ) reported that in the second quarter of fiscal the company was featured in the “Health Smart” television news show. The program effectively showed the potential of the company’s technology platform. In addition, Craig Dionne commenced writing Chairman’s blog designed to educate, inform, and offer perspective to shareholders on company’s drug advancement and business development.
PCG Advisory Group, company’s Investor Relations agency orchestrated a series of investor outreach programs and road shows. Since then, Genspera has introduced to renowned institutional funds and individuals that can turn into long-term investors for the company.
The highlights
Genspera released final results from its Phase 2 liver cancer study in which a total of 25 enrollments were treated with mipsagargin. The participants in trial showed a median time to development of 4.5 months, almost double the time seen in prior trials with ineffective agents or placebo. 63% percent of patients recorded stable disease at two months, and moreover mipsagargin was demonstrated to dramatically lower blood flow in liver tumors.
The study
Santosh Kesari, MD, PhD, the Principal Investigator of clinical trial, obtained a RO-1 grant of $1.6 million from the FDA for preclinical work and biomarker progress in support of the underway mipsagargin clinical trial in humans.
This study is being conducted in La Jolla CA. Sufficiently promising data were recorded in the first stage of the underway Phase 2 trial of mipsagargin in glioblastoma patients to support continuation of enrollment for an extended trial. The company has now treated 15 patients in Phase 2 glioblastoma clinical study, and continues licensing, partnering, and research collaboration talks with regional and multinational pharmaceutical companies.
In last trading session, the stock price of Genspera Inc (OTCMKTS:GNSZ) gained more than 5% to close the trading session at $0.900. The gains came at a share volume of 1.18 million compared to monthly average share volume of 153,879.
